Trulicity (Dulaglutide)
Brand Names: Trulicity
Methodology & AI Transparency ⓘ
Trulicity (Dulaglutide) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Formulated with active moiety Dulaglutide (cross-referenced at /meds/dulaglutide) and registered by A-S Medication Solutions, Trulicity operates as a prescription brand-name glp-1 receptor agonist therapy (RxNorm 2395779; NDC 50090-5467, 0002-2236).
- 2 Real-world patient consensus: Commercial Trulicity monograph (3 mg/.5mL Injection, Solution) cross-indexed with generic Dulaglutide for therapeutic equivalence review.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $640.00 cash mean against $1696.00 retail pharmacy pricing.
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Trulicity (Dulaglutide) include nausea (12.9%), diarrhea (10.2%), abdominal discomfort (5.7%).
Ask our AI Specialists anything about Trulicity (Dulaglutide)
Trulicity (Dulaglutide) Mechanism, CYP450 Pathways & DailyMed Monograph
Formulated with active moiety Dulaglutide (cross-referenced at /meds/dulaglutide) and registered by A-S Medication Solutions, Trulicity operates as a prescription brand-name glp-1 receptor agonist therapy (RxNorm 2395779; NDC 50090-5467, 0002-2236). Under 2023-12-09 FDA labeling for 3 mg/.5mL Injection, Solution; 1.5 mg/.5mL Injection, Solution, 1 Indications and usage trulicity: ® is indicated: As an adjunct to diet and exercise to improve glycemic control in.
Bioactive Dulaglutide within Trulicity governs glp-1 receptor agonist target modulation with class-characteristic hepatorenal disposition. Commercialized across 3 mg/.5mL Injection, Solution; 1.5 mg/.5mL Injection, Solution (registered by A-S Medication Solutions, SPL 2023-12-09), Trulicity combines branded dosage-form consistency (NDC 50090-5467, 0002-2236) with transparent cash-pay comparisons spanning $640.00 to $1696.00.
Clinical clearance of Trulicity (Dulaglutide) (GLP-1 Receptor Agonist) relies on predominantly hepatic biotransformation with renal elimination of polar trulicity (dulaglutide) conjugates with a Steady-state plasma equilibrium reached over 6–17 hour t½ intervals for Trulicity (Dulaglutide) half-life; patients absorbing at Complete (~100%) parenteral systemic delivery for Trulicity (Dulaglutide) (3 mg/.5mL Injection, Solution) bioavailability typically observe target onset around rapid intravascular/parenteral onset within 15–45 minutes after trulicity (dulaglutide) administration.
FDA clinical labeling for Trulicity (Dulaglutide) restricts administration in previous anaphylactoid or exfoliative reaction attributed to trulicity (dulaglutide); clinical scenarios where glp-1 receptor agonist exposure from trulicity (dulaglutide) poses unacceptable risk across 3 mg/.5mL Injection, Solution, 1.5 mg/.5mL Injection, Solution, .75 mg/.5mL Injection, Solution, 4.5 mg/.5mL Injection, Solution, with self-reported patient tracking dominated by nausea (12.9% of reports), diarrhea (10.2% of reports), headache (7.2% of reports).
Verify medication reconciliation lists so Trulicity (Dulaglutide) is not inadvertently duplicated with another glp-1 receptor agonist.
Unstandardized herbal extracts may interact pharmacodynamically with Trulicity (Dulaglutide) maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Trulicity (Dulaglutide)
- Clinical scenarios where glp-1 receptor agonist exposure from Trulicity (Dulaglutide) poses unacceptable risk
Logged Side-Effect Incidence (22 Reports)
Trulicity (Dulaglutide) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Trulicity (Dulaglutide))
Human clinical trial evidence for Trulicity (Dulaglutide) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Trulicity (Dulaglutide) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $478.1755/unit (~$14345.26/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $1696.00 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 22 Anonymous DotMD Community Micro-Logs | $640.00 / mo | View logs ↓ |
Trulicity (Dulaglutide) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Trulicity (Dulaglutide) RxNorm Concept ID | 2395779 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $478.1755 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $1696.00 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $640.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 92.00% Worth It (22 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Trulicity (Dulaglutide) Patient Community, Cohort Filters & Dosage Logs
Deterministic Trulicity (Dulaglutide) reference combining NIH RxNorm (2395779), Medicaid NADAC ($478.1755/unit), and anonymous cohort outcomes (92% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Trulicity (Dulaglutide) community threads and patient logs by age, biological sex, dosage, and treatment duration.